PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21990321-5	2011	Mechanistic investigations revealed that the status of the O-glycans attached to the EGFR was altered by GALNT2, changing EGFR responses after EGF binding.	o-glycans	59-68	epidermal growth factor receptor	Homo sapiens	85-89	
21990321-5	2011	Mechanistic investigations revealed that the status of the O-glycans attached to the EGFR was altered by GALNT2, changing EGFR responses after EGF binding.	o-glycans	59-68	polypeptide N-acetylgalactosaminyltransferase 2	Homo sapiens	105-111	
21990321-5	2011	Mechanistic investigations revealed that the status of the O-glycans attached to the EGFR was altered by GALNT2, changing EGFR responses after EGF binding.	o-glycans	59-68	epidermal growth factor receptor	Homo sapiens	122-126	
21990321-6	2011	Inhibiting EGFR activity with erlotinib decreased the malignant characters caused by siRNA-mediated knockdown of GALNT2 in HCC cells, establishing the critical role of EGFR in mediating the effects of GALNT2 expression.	Erlotinib Hydrochloride	30-39	epidermal growth factor receptor	Homo sapiens	11-15	
21990321-6	2011	Inhibiting EGFR activity with erlotinib decreased the malignant characters caused by siRNA-mediated knockdown of GALNT2 in HCC cells, establishing the critical role of EGFR in mediating the effects of GALNT2 expression.	Erlotinib Hydrochloride	30-39	polypeptide N-acetylgalactosaminyltransferase 2	Homo sapiens	113-119	
21990321-6	2011	Inhibiting EGFR activity with erlotinib decreased the malignant characters caused by siRNA-mediated knockdown of GALNT2 in HCC cells, establishing the critical role of EGFR in mediating the effects of GALNT2 expression.	Erlotinib Hydrochloride	30-39	polypeptide N-acetylgalactosaminyltransferase 2	Homo sapiens	201-207